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The 2 articles that comprise this In Review1,2 use different methods to review their respective literatures. 
In the first, Dr Pim Cuijpers and colleagues1 conduct a 
meta-analysis of RCTs involving CBT in the treatment of 
adult depression and find CBT superior to various control 
conditions, comparable to alternative interventions, and 
better than medication alone when added in combination. 
In the second, Dr Jan Spijker and colleagues2 chose to do 
a qualitative review, given the limited number of relevant 
RCTs that focused on chronic major depressive disorder, 
and concluded that treatment was superior to its absence but 
that multiple successive interventions may be necessary. 
Both sets of conclusions seem reasonable given the 
available data.
We come from different traditions and have different 
levels of comfort with the approaches used in the reviews. 
Dr Hollon has spent his career doing RCTs and prefers 
reviews that emphasize the findings from well-conducted 
studies. Dr Cuijpers is an experienced quantitative 
researcher who deals with concerns regarding study quality, 
using meta-regressions to explore the study characteristics 
that influence the estimated effects. As we concur that both 
reviews were nicely implemented examples of their genres, 
we chose to use this editorial to comment on differences 
arising from our different perspectives.
Do quantitative reviews obscure differences between 
different treatments? Dr Cuijpers and colleagues1 
concluded, based on their meta-analysis, that CBT was 
superior to control conditions and not different than 
alternative interventions. Hollon and Ponniah3 arrived at 
similar but not identical conclusions in a recent qualitative 
review that required a minimum number of well-conducted 
studies to draw an inference regarding treatment impact. 
Using the criteria adapted from US Food and Drug 
Administration guidelines to identify empirically supported 
treatments, a treatment was said to be efficacious if it was 
better than its absence in at least 2 studies conducted by 
different research groups (possibly if only one) and specific 
if it was superior conditions that controlled for the generic 
effects of simply going into treatment.4 Using these criteria, 
Hollon and Ponniah3 concluded that CBT was efficacious 
and specific, and came to the same conclusions regarding 
IPT, BA, PST, and ADs. Where they differed from Dr 
Cuijpers and colleagues1 was in concluding that both 
psychodynamic psychotherapy and EXP were only possibly 
efficacious (owing to the paucity of supportive trials in 
fully clinical populations) and drew no conclusions at all 
regarding supportive psychotherapy (to the extent that it 
differed from EXP). Quantitative reviews that estimate the 
average magnitude of effect across all published studies in 
a literature typically find no differences among bona fide 
therapies, whereas qualitative reviews that look for high-
quality studies sometimes do. For example, ADs represent 
the current standard of treatment for depression and pill-
placebos a particularly rigorous control. We can find studies 
in which the psychotherapy of interest was as efficacious 
as medications and superior pill-placebo for CBT,5,6 IPT,7 
BA,8 and PST,9 but not for other kinds of psychotherapies. 
Abbreviations
AD antidepressant
BA behavioural activation
CAU care as usual
CBT cognitive-behavioural therapy
ES effect size
EXP experiential psychotherapy
IPT interpersonal psychotherapy
PST problem-solving therapy
RCT randomized controlled trial
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If we were to choose among the different psychotherapies, 
do we choose one that has been shown to be at least the 
equal of the AD (when it is superior to the pill-placebo)? 
The typical quantitative review suggests that this does not 
matter. The 2 approaches especially diverge when translated 
into treatment guidelines. Although quantitative reviews 
suggest that all bona fide treatments are equally effective, 
guidelines tend to emphasize the best-supported treatments. 
If no comparisons with medication or other therapies are 
available, both approaches agree that such treatments 
should not be used in clinical practice.
Does quality of implementation matter? Closely related 
is the issue of quality of implementation. Dr Cuijpers 
and colleagues1 addressed study quality and found that 
the inclusion of lower-quality studies inflates the size of 
the psychotherapy effect. This was a nice methodological 
feature that highlights the risk of interpreting ESs in an 
uncritical fashion. However, the features they considered 
(adequate generation of allocation sequence, concealment 
of allocation to conditions, prevention of knowledge of the 
allocated intervention to assessors to outcomes, and dealing 
with incomplete data) all concern the confidence one can 
have in attributing the effects observed to the experimental 
manipulation (internal validity). Also important is whether 
the interventions were implemented in the manner intended. 
Quality of implementation can vary markedly across 
different studies and this can contribute to differences in the 
outcomes observed. For example, CBT was less efficacious 
than medication and no better than pill-placebo among 
patients, with more severe depressions in both the National 
Institute of Mental Health Treatment of Depression 
Collaborative Research Program7 and the Seattle study,8 but 
as efficacious as medications and superior to pill-placebo 
in 2 others.5,6 The first 2 trials used less experienced CBT 
therapists and provided only delayed off-site supervision, 
whereas the latter 2 trials used experienced CBT provided 
with session-by-session supervision. It is not clear that it is 
reasonable to lump all 4 trials together. In a meta-analysis 
of the association between study quality and outcome in 
treatments of depression, no association was found between 
ES and the use of a manual, the training of therapists, and 
whether treatment integrity was checked in the trial.10 
However, it is not clear that the factors included in those 
meta-regressions would have captured the differences 
described above.
Does severity moderate outcome? The 2 trials that assessed 
pretreatment severity as a moderating variable found 
evidence of specificity only among patients with more 
severe depressions.7,8 This relation also seems to hold 
for medication treatment.11 Simply put, it appears that 
treatment specificity may only matter when dealing with 
patients with more severe depressions. For most patients, 
anything is better than nothing (most treatments work better 
than their absence) and for most patients nothing is better 
than anything else (it does not matter what you do so long 
as you do something). That may account for why supportive 
psychotherapy fares as well as it does in quantitative 
reviews; if most patients do not require an intervention with 
specific effects to get better than nonspecific treatments are 
likely not to differ from treatments with specific effects 
when averaged across the literature. In that regard it is of 
interest to note that including mean pretreatment severity 
at the study level in meta-regressions failed to detect the 
moderating effect of severity found in patient-level data.12 
Moreover, is it possible that we are missing other instances 
of moderation by relying on study-level indices rather than 
patient-level variation?
Is there variation in CAU? Dr Cuijpers and colleagues1 are 
to be congratulated for subdividing their control conditions 
into different categories; their meta-regressions indicated 
that ESs were larger for wait-lists (0.83) than for either 
CAU (0.59) or placebo controls (0.51). These categories 
likely reflect the very real distinction between determining 
whether a treatment works better than its absence (efficacy) 
and whether it works for reasons beyond the simple 
provision of generic treatment (specificity). Our only 
concern is with the greater heterogeneity in the placebo 
and especially the CAU comparisons. Our reading of the 
literature suggests that CAU varies greatly across settings. 
In some instances it involves little actual care, whereas 
in other settings it can be quite rich and approaches what 
is provided in alternative treatments. The same concern 
may be raised about the placebo–other category. It may be 
useful to specify the actual amount of care provided in these 
control conditions and test whether greater specification can 
reduce heterogeneity.
How important are enduring effects? In raising these points, 
we want to emphasize that we found much to like about 
both reviews1,2 and thought their methods were outstanding. 
We strongly concur with Dr Cuijpers and colleagues1 who 
emphasized the importance of enduring effects not found 
for medication. At its best, psychotherapy is no better 
than medications regarding the speed and magnitude of 
its effects and securing that effect depends on the quality 
of implementation (at least among patients with more 
severe depression). That said, the main advantage of CBT 
is that it appears to have an enduring effect not found for 
medications.13 In a chronically recurrent disorder such as 
depression, that is a very welcome effect that can reduce the 
cost of treatment.
In conclusion, regarding the 2 different approaches to 
writing reviews on treatments of depression, we can only 
conclude that both are needed, and both have a unique 
contribution to our understanding of treatments. The 2 In 
Review papers in this issue are excellent illustrations of 
that.
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